LD Logo.png
SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Reminds Investors of Pending Securities Class Action Lawsuit against AstraZeneca plc and Encourages Investors to Inquire About the Lead Plaintiff Position Before the March 29, 2021 Lead Plaintiff Deadline
04 févr. 2021 16h51 HE | Lowey Dannenberg, P.C.
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a federal securities class action...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca and iRhythm Technologies and Encourages Investors to Contact the Firm
03 févr. 2021 20h00 HE | Bragar Eagel & Squire
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
LD Logo.png
SHAREHOLDER ALERT: Lowey Dannenberg, P.C. Announces Filing of Securities Class Action Lawsuit Against AstraZeneca plc on Behalf of Investors Who Acquired Shares from May 21, 2020 to November 20, 2020 and Encourages Investors to Inquire About the Lead Plaintiff Position Before the March 29, 2021 Lead Plaintiff Deadline
28 janv. 2021 13h23 HE | Lowey Dannenberg, P.C.
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a federal securities class action...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
12 janv. 2021 10h05 HE | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
logo (2).jpg
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK
30 déc. 2020 07h00 HE | Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK           Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”...
BES_Mark.jpg
ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm
15 déc. 2020 19h45 HE | Bragar Eagel & Squire
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout
14 déc. 2020 18h20 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible...
logo (2).jpg
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19
23 nov. 2020 07h00 HE | Oxford BioMedica plc
Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19           Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the...
RevolutionLogo.png
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
24 oct. 2020 09h45 HE | Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
INNATEvertnoir.png
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
23 oct. 2020 01h00 HE | INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...